BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24239173)

  • 1. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells.
    Tsubaki M; Komai M; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
    Leuk Res; 2014 Jan; 38(1):121-30. PubMed ID: 24239173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells.
    Tsubaki M; Satou T; Itoh T; Imano M; Komai M; Nishinobo M; Yamashita M; Yanae M; Yamazoe Y; Nishida S
    Leuk Res; 2012 Oct; 36(10):1315-22. PubMed ID: 22819074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells.
    Tsubaki M; Takeda T; Ogawa N; Sakamoto K; Shimaoka H; Fujita A; Itoh T; Imano M; Ishizaka T; Satou T; Nishida S
    Leuk Res; 2015 Apr; 39(4):445-52. PubMed ID: 25726084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
    Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
    Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells.
    Tabata M; Tsubaki M; Takeda T; Tateishi K; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
    BMC Complement Med Ther; 2020 Mar; 20(1):84. PubMed ID: 32171300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
    Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells.
    Tabata M; Tsubaki M; Takeda T; Tateishi K; Maekawa S; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
    Clin Exp Med; 2020 Feb; 20(1):63-71. PubMed ID: 31650359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
    Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
    Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition.
    Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN
    Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
    Duan Z; Zhang J; Ye S; Shen J; Choy E; Cote G; Harmon D; Mankin H; Hua Y; Zhang Y; Gray NS; Hornicek FJ
    BMC Cancer; 2014 Sep; 14():681. PubMed ID: 25236161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
    Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
    Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
    Arora A; Seth K; Kalra N; Shukla Y
    Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB.
    Tsubaki M; Takeda T; Tomonari Y; Koumoto YI; Imano M; Satou T; Nishida S
    Lab Invest; 2019 Jan; 99(1):72-84. PubMed ID: 30353128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.
    Romagnoli M; Séveno C; Wuillème-Toumi S; Amiot M; Bataille R; Minvielle S; Barillé-Nion S
    Br J Haematol; 2009 Apr; 145(2):180-9. PubMed ID: 19298592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
    Li X; Hong L; Zhao Y; Jin H; Fan R; Du R; Xia L; Luo G; Fan D
    Biochem Cell Biol; 2007 Dec; 85(6):741-50. PubMed ID: 18059532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.